Rasagiline ratiopharm (Rasagiline)

What Is Rasagiline ratiopharm and What Is It Used For?

Rasagiline ratiopharm belongs to a class of medications known as monoamine oxidase type B (MAO-B) inhibitors. It is specifically approved for the treatment of idiopathic Parkinson's disease in adult patients. The medication can be prescribed as a standalone treatment (monotherapy) for patients in the early stages of Parkinson's disease, or as an add-on therapy alongside levodopa for patients with more advanced disease who experience motor fluctuations.

Parkinson's disease is a progressive neurodegenerative disorder characterized by the loss of dopamine-producing neurons in a region of the brain called the substantia nigra. Dopamine is a critical neurotransmitter involved in coordinating smooth, purposeful movement. As dopamine levels decline, patients develop the hallmark motor symptoms of Parkinson's disease: resting tremor, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Non-motor symptoms such as sleep disturbances, depression, and cognitive changes may also occur as the disease progresses.

Rasagiline addresses this dopamine deficiency by selectively and irreversibly inhibiting the MAO-B enzyme in the brain. MAO-B is responsible for a significant portion of dopamine metabolism in the central nervous system. By blocking this enzyme, rasagiline slows the enzymatic breakdown of dopamine, effectively increasing and sustaining dopamine levels in the striatum. This pharmacological action helps compensate for the reduced dopamine production that characterizes Parkinson's disease, leading to improvements in motor control and a reduction in the frequency and severity of motor fluctuations.

When used as monotherapy, rasagiline provides modest but clinically meaningful improvements in motor function. The TEMPO and ADAGIO clinical trials demonstrated that rasagiline monotherapy significantly improved UPDRS (Unified Parkinson's Disease Rating Scale) motor scores compared to placebo. When used as adjunctive therapy with levodopa, rasagiline reduces "off" time (periods when Parkinson's symptoms return between medication doses) by approximately 0.5 to 1 hour per day, as demonstrated in the PRESTO and LARGO trials. This reduction in off-time can have a substantial impact on patients' quality of life, enabling more consistent symptom control throughout the day.

Rasagiline ratiopharm is a generic medication manufactured by ratiopharm, containing the same active ingredient as the originator product Azilect (developed by Teva Pharmaceuticals). Generic medicines must demonstrate bioequivalence to the originator product, meaning they deliver the same amount of active substance to the bloodstream in the same manner, ensuring equivalent clinical efficacy and safety. Other therapeutically equivalent rasagiline brands include Rasagilin Glenmark, Rasagiline Bluefish, Rasagilin Krka, Rasagilin STADA, Rasagiline Viatris, and Rasagiline Accord.

What Should You Know Before Taking Rasagiline ratiopharm?

Contraindications

There are several important situations in which rasagiline must not be used. Understanding these contraindications is essential for safe treatment, and patients should provide their healthcare provider with a complete medication list and medical history before starting therapy.

If you have been taking rasagiline and need to start an MAO inhibitor or pethidine, you must wait at least 14 days after your last dose of rasagiline. This washout period is critical because rasagiline irreversibly inhibits MAO-B, and the body needs time to synthesize new MAO-B enzyme before it is safe to introduce another MAO-active drug. Failure to observe this washout period could result in dangerous interactions, including hypertensive crisis or serotonin syndrome, both of which can be life-threatening.

Warnings and Precautions

Several important precautions should be discussed with your healthcare provider before and during treatment with rasagiline. Your doctor will evaluate your overall health, concurrent medications, and individual risk factors before prescribing rasagiline, and may adjust your monitoring plan based on these considerations.

Liver problems: If you have mild to moderate liver impairment, your doctor will need to carefully consider whether rasagiline is appropriate for you. The medication is metabolized primarily by the liver enzyme CYP1A2, and reduced liver function may lead to increased drug exposure and a higher risk of adverse effects. Rasagiline is contraindicated in patients with severe hepatic impairment. For patients with mild impairment, standard dosing may be used with careful monitoring, while moderate impairment generally warrants additional caution and may require alternative therapy.

Skin cancer risk: Treatment with rasagiline may potentially increase the risk of melanoma (skin cancer). This association has been observed in epidemiological studies, although it is unclear whether this is related to the medication itself, Parkinson's disease, or other confounding factors. Patients with Parkinson's disease generally have a higher baseline risk of melanoma regardless of treatment. Patients on rasagiline should have regular dermatological examinations and should report any new or suspicious skin changes, moles that change in size, shape, or color, or unusual skin lesions to their doctor promptly.

Impulse control disorders: Rasagiline, like other dopaminergic medications used in Parkinson's disease, may cause impulse control disorders. These are behavioral changes where patients cannot resist the urge to perform certain activities that could be harmful to themselves or their family. Reported impulse control disorders include pathological gambling, compulsive shopping or spending, binge eating, compulsive sexual behavior, and an abnormally high sex drive. These changes may be gradual and may not be recognized by the patient. If you or your family members notice any such behavioral changes, contact your healthcare provider immediately, as dose adjustment or treatment discontinuation may be necessary.

Drowsiness and sudden sleep onset: Rasagiline may cause somnolence (excessive daytime sleepiness) and episodes of suddenly falling asleep during daily activities. This risk is particularly elevated when rasagiline is combined with other dopaminergic medications such as levodopa or dopamine agonists. Patients should exercise caution when driving or operating machinery, especially during the initial treatment period and any time the dose of concomitant dopaminergic therapy is adjusted. If you experience any sudden sleep episodes, you should discontinue driving immediately and inform your doctor.

Cardiovascular considerations: While rasagiline is generally well-tolerated, uncommon cases of cardiovascular events including stroke and myocardial infarction have been reported. Patients with a history of cardiovascular disease, uncontrolled hypertension, or cerebrovascular disease should be carefully evaluated before starting treatment, and blood pressure should be monitored during therapy, especially in the first few weeks.

Pregnancy and Breastfeeding

The safety of rasagiline during pregnancy has not been established in clinical studies. Animal studies are insufficient to fully assess reproductive toxicity. Because the potential risk to the developing fetus is unknown, rasagiline should be avoided during pregnancy unless the potential benefit clearly outweighs the possible risk. Women of childbearing potential should discuss appropriate contraceptive measures with their healthcare provider, and should inform their doctor immediately if pregnancy is suspected or confirmed during rasagiline therapy.

It is not known whether rasagiline or its metabolites are excreted in human breast milk. Laboratory studies suggest that rasagiline may inhibit prolactin secretion and thus interfere with lactation. Given the potential for adverse effects in nursing infants, a decision should be made whether to discontinue breastfeeding or to discontinue rasagiline therapy, taking into account the importance of the medication to the mother. Consult your doctor for personalized advice based on your individual clinical situation.

Children and Adolescents

Rasagiline is not indicated for use in children and adolescents under 18 years of age. Parkinson's disease is exceedingly rare in this population, and the safety and efficacy of rasagiline have not been studied in pediatric patients. There is no relevant use of rasagiline in the pediatric population for its approved indication, and alternative treatments are available for the few pediatric conditions that might theoretically benefit from dopaminergic therapy.

How Does Rasagiline ratiopharm Interact with Other Drugs?

Drug interactions with rasagiline can be clinically significant and potentially dangerous. The mechanism of action of rasagiline as an MAO-B inhibitor means it interacts with the serotonergic and adrenergic systems, creating the potential for serious pharmacodynamic interactions with a range of medications. Additionally, rasagiline is metabolized by the hepatic enzyme CYP1A2, leading to pharmacokinetic interactions with drugs that inhibit or induce this enzyme. Always inform your doctor or pharmacist about all medications you are taking, including prescription drugs, over-the-counter products, herbal supplements, and vitamins.

Major Interactions (Contraindicated or Avoid)

Moderate Interactions (Use with Caution)

Serotonin syndrome is a potentially life-threatening condition that can occur when serotonergic medications are combined with MAO inhibitors. Symptoms include agitation, confusion, rapid heart rate, elevated blood pressure, dilated pupils, muscle twitching, tremor, hyperthermia, and sweating. If you experience any combination of these symptoms while taking rasagiline, seek immediate medical attention. Early recognition and discontinuation of serotonergic agents is essential for management.

Hypertensive crisis is another potentially severe adverse reaction that may occur with MAO inhibitor interactions. Warning signs include severe headache, nausea, vomiting, sweating, palpitations, chest pain, and visual disturbances. Although selective MAO-B inhibitors like rasagiline carry a lower risk of the "cheese effect" (tyramine-induced hypertension) compared to non-selective MAO inhibitors, caution is still warranted when combining rasagiline with tyramine-rich foods or sympathomimetic agents.

What Is the Correct Dosage of Rasagiline ratiopharm?

Rasagiline dosing is simple compared to many other Parkinson's medications, as no titration is required. The starting dose is also the maintenance dose, and the same dose applies across most patient populations. Consistent daily administration is key to maintaining stable MAO-B inhibition and optimal symptom control.

Adults

Unlike some Parkinson's medications, rasagiline does not require dose titration. The starting dose is the maintenance dose. Clinical trials have shown that 1 mg once daily provides optimal efficacy without increasing the risk of adverse effects compared to lower doses. In the TEMPO trial, 2 mg daily did not provide additional benefit over 1 mg and was associated with more side effects. Therefore, exceeding the recommended 1 mg daily dose is not advisable.

When rasagiline is added to existing levodopa therapy, your doctor may consider reducing the levodopa dose to minimize dopaminergic side effects such as dyskinesia, especially in patients with advanced Parkinson's disease. The decision to adjust levodopa is individualized based on clinical response and tolerability.

Elderly Patients

No dose adjustment is required for elderly patients. Rasagiline has been extensively studied in older adults, as Parkinson's disease predominantly affects this population. The pharmacokinetics of rasagiline are not significantly altered by age. However, elderly patients may be more susceptible to orthostatic hypotension and should be monitored accordingly, particularly during the initial weeks of treatment. Fall risk should also be assessed, as both Parkinson's disease and orthostatic effects can contribute to falls.

Hepatic Impairment

Patients with mild hepatic impairment should use rasagiline with caution, as drug metabolism may be reduced and plasma levels may be elevated compared to patients with normal liver function. Rasagiline is contraindicated in patients with severe hepatic impairment. For moderate hepatic impairment, the decision to use rasagiline should be made on an individual basis by the treating physician, weighing the benefits against the risks of increased drug exposure. Liver function tests may be advisable before starting therapy and periodically during treatment.

Renal Impairment

No dose adjustment is required for patients with renal impairment. Rasagiline and its metabolites are primarily eliminated via hepatic metabolism and subsequent renal excretion, but the kidneys play a relatively minor role in overall drug clearance. Standard dosing can be used in patients with mild to severe renal impairment without increased risk of drug accumulation.

Children

Rasagiline is not indicated for use in children or adolescents under 18 years of age. There are no clinical data to support its use in this population, and alternative treatment options should be considered if dopaminergic therapy is ever required in a pediatric patient (under specialist supervision).

Missed Dose

If you forget to take your daily dose of rasagiline, do not take a double dose to make up for the missed one. Simply take the next dose at the usual scheduled time. Because rasagiline irreversibly inhibits MAO-B, a single missed dose is unlikely to cause a significant return of symptoms, as the enzyme inhibition persists until new MAO-B is synthesized. If you frequently forget doses, consider using a pill organizer or setting a daily reminder on your phone to help maintain consistent therapy.

Overdose

Symptoms reported following rasagiline overdose include mild euphoria (a mild form of mania), extremely elevated blood pressure, and serotonin syndrome. Serotonin syndrome symptoms may include agitation, confusion, tremor, rapid heart rate, high body temperature, and excessive sweating. Treatment of overdose is supportive and symptomatic, with monitoring of vital signs and cardiac function. There is no specific antidote for rasagiline overdose. Benzodiazepines may be used for agitation, and active cooling measures may be required for severe hyperthermia.

Stopping Treatment

Do not stop taking rasagiline without first consulting your doctor. While abrupt discontinuation of rasagiline is generally not associated with a withdrawal syndrome (unlike some other dopaminergic medications), stopping therapy may lead to worsening of Parkinson's disease symptoms. Because rasagiline irreversibly inhibits MAO-B, enzyme activity does not return immediately upon discontinuation — approximately 2 weeks are required for normal MAO-B function to be restored through synthesis of new enzyme. This prolonged effect is important when planning transitions to other medications. Your doctor will advise you on how to manage your treatment plan if discontinuation is necessary.

What Are the Side Effects of Rasagiline ratiopharm?

Like all medicines, rasagiline can cause side effects, although not everyone experiences them. The type and frequency of side effects may differ depending on whether rasagiline is used alone or in combination with levodopa. When used with levodopa, dyskinesia (involuntary movements) is the most commonly reported side effect, as the increased dopamine levels from MAO-B inhibition enhance the effects of levodopa. Most side effects are mild to moderate in severity and may resolve with continued treatment as the body adjusts to the medication.

If you notice any side effects, including any not listed above, inform your healthcare provider. Reporting suspected adverse reactions after marketing authorization is important, as it allows ongoing monitoring of the benefit-risk balance of the medicine. You can report side effects to your national health authority (such as the EMA in Europe, FDA in the United States, or MHRA in the United Kingdom) or through your healthcare provider.

It is worth noting that many of these side effects overlap with the symptoms of Parkinson's disease itself. For example, falls, depression, and orthostatic hypotension are common in Parkinson's patients regardless of medication use. Your doctor will help distinguish between disease-related symptoms and medication-related side effects, and may adjust treatment accordingly. Keep a symptom diary if you notice unusual changes during treatment, which can help your healthcare team evaluate the clinical picture.

Can You Drive While Taking Rasagiline ratiopharm?

Both Parkinson's disease itself and treatment with rasagiline can affect your ability to safely drive a vehicle or operate machinery. Rasagiline may cause dizziness, drowsiness, and in some cases, episodes of suddenly falling asleep during normal daily activities without warning or without feeling drowsy beforehand. These effects can have serious safety implications, particularly when driving, operating heavy machinery, or working at heights.

The risk of somnolence and sudden sleep episodes is particularly increased when rasagiline is combined with other dopaminergic medications commonly used in Parkinson's disease, or when patients consume alcohol. If you have experienced somnolence or sudden sleep attacks at any time during rasagiline treatment, you should not drive or operate machinery. These episodes may occur without warning and can be dangerous even at relatively low doses.

Before starting rasagiline, discuss with your doctor whether you can safely continue driving. You are personally responsible for assessing whether you are fit to drive or perform tasks requiring alertness. Your ability may be affected by the medication's effects and side effects as described throughout this article. If you are uncertain, consult your doctor or pharmacist. In some jurisdictions, there are specific legal requirements for reporting medical conditions and treatments that may affect driving ability — check local regulations if in doubt.

How Should You Store Rasagiline ratiopharm?

Proper storage of rasagiline is important to maintain the medication's efficacy and safety. The tablets should be stored at a temperature not exceeding 25°C (77°F). Keep the medication in its original packaging (blister pack or bottle) to protect it from moisture and light. Avoid storing in the bathroom, kitchen, or near windows where temperature and humidity may fluctuate significantly.

If your rasagiline comes in a bottle, note that the shelf life after first opening is 2 months. After this period, any remaining tablets should be discarded even if the printed expiration date has not passed. Write the date of first opening on the bottle to help you track this. Blister-packaged tablets do not have this restriction and can be used until the expiration date printed on the packaging.

Always keep this medication out of the sight and reach of children. Accidental ingestion by children can have serious consequences, particularly given rasagiline's pharmacological effects and drug interaction potential. Do not use rasagiline after the expiration date (EXP) printed on the carton, blister, or bottle. The expiration date refers to the last day of that month.

Do not dispose of medications via wastewater or household waste. Ask your pharmacist about proper disposal methods for medications that are no longer needed or have expired. Many pharmacies operate medication take-back programs. These measures help protect the environment and prevent accidental ingestion by others.

What Does Rasagiline ratiopharm Contain?

Each Rasagiline ratiopharm tablet contains 1 mg of rasagiline, present as the tartrate salt (rasagiline tartrate). Rasagiline is the pharmacologically active component responsible for MAO-B inhibition and the therapeutic effect in Parkinson's disease.

The inactive ingredients (excipients) that make up the tablet formulation typically include:

• Microcrystalline cellulose — a common tablet filler and binder
• Citric acid (anhydrous) — used as a pH modifier and stabilizer
• Pregelatinized maize starch — acts as a binder and disintegrant to help the tablet dissolve
• Colloidal anhydrous silica — a flow agent that prevents ingredients from clumping
• Stearic acid — a lubricant that prevents the tablet from sticking to manufacturing equipment
• Talc — an additional lubricant and glidant
• Mannitol — a tablet filler and sweetener (present in some formulations)

Rasagiline ratiopharm tablets are typically white to off-white, round or flat tablets, approximately 7–8 mm in diameter. Exact appearance and tablet markings may vary by country and batch — always compare new supplies to previous tablets and consult your pharmacist if the appearance seems unexpected. The tablets are generally available in blister packs of 7, 10, 28, 30, 60, 100, and 112 tablets. Not all pack sizes may be marketed in every country.

If you are allergic to any of these ingredients, do not take Rasagiline ratiopharm and inform your doctor so they can prescribe an alternative rasagiline formulation with a different excipient profile, or a different MAO-B inhibitor. For the most accurate and up-to-date list of excipients for a specific product, consult the package leaflet that accompanies your medication.